1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol | 371754-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 1-[2H-5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl]-2-[3-(4-n-butyloxyphenyl)-2-methyl-2-propylamino]ethanol
• 英文别名: 2h-1,4-Benzoxazin-3(4h)-one,8-[2-[[2-(4-butoxyphenyl)-1,1-dimethylethyl]amino]-1-hydroxyethyl]-5-hydroxy-；8-[2-[[1-(4-butoxyphenyl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]-5-hydroxy-4H-1,4-benzoxazin-3-one
• CAS: 371754-06-2
• 化学式: C₂₄H₃₂N₂O₅
• 分子量: 428.528
• InChiKey: VOUKXEBXCUZGJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  100
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
  申请人：ALMIRALL SA

  公开号：WO2014060432A1

  公开（公告）日：2014-04-24

  New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

  新的吡咯三唑酮衍生物具有化学结构式（I），公开；以及它们的制备方法，包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的应用。
• [EN] MEDICAMENTS FOR INHALATION COMPRISING BETAMIMETICS AND AN ANTICHOLINERGIC AGENT<br/>[FR] MEDICAMENTS POUR INHALATION COMPORTANT DES AGENTS A ACTIVITE BETAMIMETIQUE ET ANTICHOLINERGIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005013992A1

  公开（公告）日：2005-02-17

  The present invention relates to novel pharmaceutical compositions based on beta2 agonists and salts of a new anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints, wherein the anticholinergic agent has the formula (I).

  本发明涉及基于β2激动剂和一种新的抗胆碱药盐的新型药物组合物，以及制备这些药物组合物的方法和它们在治疗呼吸道疾病中的应用，其中抗胆碱药物具有化学式(I)。
• Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
  申请人：Germeyer Sabine

  公开号：US20050107417A1

  公开（公告）日：2005-05-19

  A pharmaceutical composition comprising a compound of formula 1 wherein X − is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.

  一种包括式1的化合物的药物组合物，其中X-是带有单负电荷的阴离子，以及一种β-肾上腺素受体激动剂，可选地与药用可接受的赋形剂一起，式1的化合物和β-肾上腺素受体激动剂可选地以其对映体、对映体混合物、消旋体、溶剂化合物或水合物的形式存在，以及制备它们的方法，以及它们在治疗呼吸道疾病中的用途。
• THIAZOLYL-DIHYDRO-CHINAZOLINE
  申请人：Brandl Trixi

  公开号：US20070238746A1

  公开（公告）日：2007-10-11

  Disclosed are compounds of general formula (I), wherein the groups A, R 1 , R 2 , R a and R b have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

  揭示了一般式(I)的化合物， 其中，基团A，R1，R2，Ra和Rb具有权利要求和说明中给定的含义，其互变异构体，拉克酸盐，对映体，非对映体和它们的混合物，以及可选择的药理学上可接受的酸加盐，溶剂合物和水合物，以及制备这些噻唑基-二氢喹唑啉并将其用作药物组合物的方法。
• New CRTh2 antagonists
  申请人：Almirall, S.A.

  公开号：EP2548876A1

  公开（公告）日：2013-01-23

  The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

  本发明涉及式(I)的化合物，制备这种化合物的方法以及它们在治疗病理状况或疾病中的应用，该病理状况或疾病容易通过CRTh2拮抗活性得到改善。